TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7808491

Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfin-pyrazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin plus dipyridamole or sulfin-pyrazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study: 2695129

Group type: EXPERIMENTAL
Intervention: moclobemide
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: imipramine
Number of subjects: 490

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 490
Study: 608010

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy plus surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery plus postoperative radiotherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 100
Study: 31969067

Group type: EXPERIMENTAL
Intervention: Desirability self‐affirmed feedback (DSF)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Feasibility self‐affirmed feedback (FSF)
Number of subjects: 55
Study: 30518685

Group type: EXPERIMENTAL
Intervention: Low-dose inhaled carbon monoxide (iCO) at 100 ppm (cohort 1) or 200 ppm (cohort 2) for 90 minutes for up to 5 consecutive days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo air
Number of subjects: 12
Study: 26701762

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB)
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB) with physical therapy
Number of subjects: 591
Study: 25689563

Group type: EXPERIMENTAL
Intervention: Ketogenic Mediterranean diet with ω‐3 supplementation (KDO3)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ketogenic Mediterranean diet without ω‐3 supplementation (KD)
Number of subjects: 34
Study: 23317958

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Smokers and ex-smokers who smoked >20 cigarettes a day
Number of subjects: 293

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 293
Study: 20494360

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 69

Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 69
Study: 18230699

Group type: EXPERIMENTAL
Intervention: Urinary EtG
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Urinary EtS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GTOL/5‐HIAA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ethanol testing in urine
Number of subjects: 10
Study: 15218006

Group type: EXPERIMENTAL
Intervention: Upper half of endometrial cavity (Group I, n = 200)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Lower half of endometrial cavity (Group II, n = 200)
Number of subjects: 400
Study: 12525911

Group type: EXPERIMENTAL
Intervention: LigaSure haemorrhoidectomy
Number of subjects: 56
Study: 9818657

Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Arthritis Impact Measurement Scale 2 (AIMS2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Medical Outcome Study Short Form Health Survey (SF‐36)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Standardized Response Means (SRM) analysis
Number of subjects: 70

Group type: COMPARATOR
Intervention: None of the instruments
Number of subjects: 70
Study: 7631599

Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy
Number of subjects: 26
Study: 2654467

Group type: EXPERIMENTAL
Intervention: Obsidan (0.1 mg/kg intravenously, then orally for 2-3 days every 3-4 hours, followed by 60-120 mg per 24 hours)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Traditional treatment (control group)
Number of subjects: 67
Study: 132326

Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intra‐discal hydrocortisone
Number of subjects: 20
Study: 31924485

Group type: EXPERIMENTAL
Intervention: Intermittent oroesophageal (IOE) tube feeding
Number of subjects: 97

Group type: COMPARATOR
Intervention: Continuous nasogastric tube feeding
Number of subjects: 97
Study: 29858773

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Psychodynamic Psychotherapy
Number of subjects: 5
Study: 27279083

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned)
Number of subjects: 1007
Study: 26323732

Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's anesthesia (group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No sub‐Tenon's anesthesia (group 1)
Number of subjects: 40
Study: 24381911

Group type: EXPERIMENTAL
Intervention: Submucosal tramadol (2 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic solution (control)
Number of subjects: 60
Study: 20854284

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 811

Group type: COMPARATOR
Intervention: No Palivizumab
Number of subjects: 811
Study: 19388886

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (basic analgesic regimen of paracetamol and diclofenac)
Number of subjects: 53
Study: 16885230

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 38
Study: 14993578

Group type: EXPERIMENTAL
Intervention: Metadate CD (MCD) 20 mg, 40 mg, 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metadate CD (MCD) 40 mg, 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concerta (CON) 18 mg, 36 mg, 54 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metadate CD (MCD) and Concerta (CON)
Number of subjects: 0
Study: 11713063

Group type: EXPERIMENTAL
Intervention: Diagnosis of glaucoma (possible, probable, definite)
Number of subjects: 4744

Group type: EXPERIMENTAL
Intervention: Positive family history of glaucoma
Number of subjects: 4744

Group type: EXPERIMENTAL
Intervention: Not attended an eye care provider in the last 2 years
Number of subjects: 4744
Study: 9222707

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension (2 x 2 g/day)
Number of subjects: 208

Group type: COMPARATOR
Intervention: No additional medicine (Control)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control (No sucralfate)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 208
Study: 7897780

Group type: EXPERIMENTAL
Intervention: Topical application of a nasal decongestant
Number of subjects: 78
Study: 3310717

Group type: EXPERIMENTAL
Intervention: Mixed grass pollen allergens from rye grass, timothy grass, cultivated rye and velvet grass (administered daily for 1 year).
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (administered daily for 1 year).
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Mixed grass pollen allergens (administered daily for 1 year).
Number of subjects: 42
Study: 31529220

Group type: EXPERIMENTAL
Intervention: Indigo naturalis (0.5-2.0 g daily)
Number of subjects: 86
Study: 30442034

Group type: EXPERIMENTAL
Intervention: leave‐one‐out potential outcomes estimator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 27787540

Group type: EXPERIMENTAL
Intervention: Oral voriconazole (loading dose of 400 mg twice daily for 24 hours, followed by 200 mg twice daily for 20 days)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Oral voriconazole
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 25330906

Group type: EXPERIMENTAL
Intervention: Intervention group (new contraceptive method introduced, providers trained, community-wide information dissemination)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22023889

Group type: EXPERIMENTAL
Intervention: Pharmacist-physician collaboration intervention involving interviews and pharmaceutical care for a year.
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (standard care without pharmacist intervention).
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Pharmacist interventions performed during the study.
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Detection of adverse drug reactions and drug interactions.
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Detection of drug interactions.
Number of subjects: 314
Study: 20027579

Group type: EXPERIMENTAL
Intervention: Manual measurement of RVEDV
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Manual measurement of LVEDV
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Manual measurement of RV ejection fraction
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Manual measurement of RV mass
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Semiautomated measurement of RV mass
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Semiautomated measurement of LV end-diastolic volume (EDV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Manual analysis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Semiautomated analysis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Interobserver reproducibility
Number of subjects: 10
Study: 18752586

Group type: EXPERIMENTAL
Intervention: Titrated low-dose misoprostol
Number of subjects: 758

Group type: COMPARATOR
Intervention: Standard induction method (vaginal dinoprostone followed by intravenous oxytocin or intravenous oxytocin alone)
Number of subjects: 758
Study: 15497668

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg (Sinopryl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisinopril/hydrochlorothiazide 20 mg/12.5 mg (Sinoretik)
Number of subjects: 0
Study: 11738168

Group type: EXPERIMENTAL
Intervention: Single fraction external beam radiation therapy (8 Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various fractionated regimens
Number of subjects: 0
Study: 9338613

Group type: EXPERIMENTAL
Intervention: Azelastine (Allergodil nasal spray)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Budesonide (Rhinocort Aqua)
Number of subjects: 14
Study: 8179082

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g intravenous at induction of anesthesia)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cefoxitin (1 g intravenous every 8 hours starting at induction, three times)
Number of subjects: 150
Study: 3662317

Group type: EXPERIMENTAL
Intervention: Nonremoval of the epithelium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Removal of the epithelium
Number of subjects: 0
Study: 31642930

Group type: COMPARATOR
Intervention: No change in reminder signs throughout the intervention period
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Signs changed weekly
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Signs changed monthly
Number of subjects: 58
Study: 30420367

Group type: EXPERIMENTAL
Intervention: Patellar mobilization therapy (PMT)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (received PMT after the study period)
Number of subjects: 208
Study: 27509602

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied to specific acupuncture points, retained for 20 min, once every two days for 6 weeks.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Meloxicam, 7.5 mg, once a day for 6 weeks.
Number of subjects: 90
Study: 25275731

Group type: EXPERIMENTAL
Intervention: Shock-absorbing insoles (SAIs)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual insoles (Control)
Number of subjects: 75
Study: 21741803

Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Tobacco intake
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 54
Study: 20642070

Group type: EXPERIMENTAL
Intervention: Nurse involvement in clinical trial implementation
Number of subjects: 0
Study: 17321111

Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg/day for 6 weeks
Number of subjects: 24
Study: 16321133

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) for five minutes while holding a static, semi-squat position
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no vibration) adopting the same weightbearing position for equal time
Number of subjects: 25
Study: 11372795

Group type: EXPERIMENTAL
Intervention: 17 g of PEG daily for 4 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PEG treatment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PEG therapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PEG laxative
Number of subjects: 23
Study: 9230807

Group type: EXPERIMENTAL
Intervention: Handsewn ileal pouch-anal anastomosis (IPAA) with anal mucosa excised
Number of subjects: 41

Group type: COMPARATOR
Intervention: Double-stapled ileal pouch-anal anastomosis (IPAA) with anal mucosa preserved
Number of subjects: 41

Group type: COMPARATOR
Intervention: Double-stapled IPAA
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 41
Study: 8434544

Group type: EXPERIMENTAL
Intervention: Slight photocoagulation (405 +/- 166 laser burns)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Heavy photocoagulation (1142 +/- 179 laser burns)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Comparison of both interventions
Number of subjects: 17

Group type: COMPARATOR
Intervention: Overall comparison of slight vs heavy photocoagulation
Number of subjects: 17
Study: 3114710

Group type: EXPERIMENTAL
Intervention: Direct extubation from intermittent mandatory ventilation rates of six to ten per minute
Number of subjects: 27

Group type: COMPARATOR
Intervention: Continuous positive airway pressure through endotracheal tubes for six hours prior to extubation
Number of subjects: 27
Study: 30624997

Group type: EXPERIMENTAL
Intervention: Hydrotubation (Elgazzar and Alalfy technique)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 31066646

Group type: EXPERIMENTAL
Intervention: Low dose regimen containing voclosporin, MMF and steroid therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard of care treatment with high dose MMF and steroids
Number of subjects: 63
Study: 28495299

Group type: EXPERIMENTAL
Intervention: VC175
Number of subjects: 300

Group type: COMPARATOR
Intervention: T380S
Number of subjects: 300
Study: 26169946

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control
Number of subjects: 51

Group type: COMPARATOR
Intervention: Leisure
Number of subjects: 51
Study: 23438203

Group type: EXPERIMENTAL
Intervention: Integrated education programme in primary care
Number of subjects: 801

Group type: COMPARATOR
Intervention: Standard practice (control group)
Number of subjects: 801
Study: 21438794

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 929

Group type: COMPARATOR
Intervention: SNRIs
Number of subjects: 929
Study: 19228538

Group type: EXPERIMENTAL
Intervention: Preoperative warm-up with standardized exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fatigued group performance
Number of subjects: 0
Study: 16517764

Group type: EXPERIMENTAL
Intervention: G-CSF therapy (subcutaneous injections of 15 microg/kg per day for 5 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 10
Study: 14656272

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin and paclitaxel
Number of subjects: 0
Study: 11093843

Group type: EXPERIMENTAL
Intervention: Modified inserts
Number of subjects: 1560

Group type: COMPARATOR
Intervention: Unmodified inserts
Number of subjects: 1560
Study: 9312920

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 8312200

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 0
Study: 27819485

Group type: EXPERIMENTAL
Intervention: Omega-3 (Ω3)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Individual-Family Psychoeducational Psychotherapy (PEP) + Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Omega-3 (Ω3) + Individual-Family Psychoeducational Psychotherapy (PEP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combined treatment (Ω3 + PEP)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Omega-3 (Ω3) monotherapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: PEP + Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: PEP
Number of subjects: 72
Study: 29620396

Group type: EXPERIMENTAL
Intervention: Additional-opportunities instruction
Number of subjects: 610

Group type: COMPARATOR
Intervention: Standard admonition
Number of subjects: 610
Study: 27454370

Group type: EXPERIMENTAL
Intervention: Family systems therapy
Number of subjects: 183

Group type: COMPARATOR
Intervention: Women's Health Education
Number of subjects: 183
Study: 25060157

Group type: EXPERIMENTAL
Intervention: Yoghurt enriched with 2 g of plant stanol ester (PS group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Yoghurt drink without extra stanols (Control group)
Number of subjects: 90
Study: 22640176

Group type: EXPERIMENTAL
Intervention: Diagnostic screening (history taking, physical examination, electrocardiography, spirometry, blood tests, and echocardiography)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 20718217

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice
Number of subjects: 33

Group type: COMPARATOR
Intervention: 0.243% sodium fluoride (negative control)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tongue brushing with either dentifrice
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Standard sodium fluoride dentifrice (during acclimation)
Number of subjects: 33
Study: 18990996

Group type: EXPERIMENTAL
Intervention: Immediate nonocclusal loading of dental implants
Number of subjects: 20

Group type: COMPARATOR
Intervention: Early nonocclusal loading of dental implants (6 weeks)
Number of subjects: 20
Study: 15385946

Group type: EXPERIMENTAL
Intervention: Est intervention
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Est Plus DASH intervention
Number of subjects: 810

Group type: COMPARATOR
Intervention: Advice Only group
Number of subjects: 810
Study: 12885699

Group type: EXPERIMENTAL
Intervention: Sibutramine treatment
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity index
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Percentage of initial body weight lost during the 6-month weight-loss phase
Number of subjects: 261
Study: 10686713

Group type: EXPERIMENTAL
Intervention: Non-pharmacological measures including changes in lifestyle and dietary habits
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional medical care (Control)
Number of subjects: 60
Study: 9124793

Group type: EXPERIMENTAL
Intervention: Shouldice procedure with local anesthesia and antibio-prophylaxy
Number of subjects: 0
Study: 1860285

Group type: EXPERIMENTAL
Intervention: Taurolin rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 0
Study: 7104143

Group type: EXPERIMENTAL
Intervention: 5 mg pindolol three times daily for 2 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 80 mg propranolol three times daily for 2 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group: young non‐smokers (YNS)
Number of subjects: 32
Study: 30638922

Group type: EXPERIMENTAL
Intervention: Dynamic Needle Tip Positioning (DNTP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 40
Study: 26250825

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 871

Group type: COMPARATOR
Intervention: Heparin + GPI
Number of subjects: 871
Study: 26853339

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Radiation Therapy (RT) at a recommended phase 2 dose of 750 mg/m(2)/wk during the last 4 weeks of RT
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Radiation Therapy (RT)
Number of subjects: 29
Study: 24408514

Group type: EXPERIMENTAL
Intervention: Topical Cyperus rotundus oil
Number of subjects: 65

Group type: COMPARATOR
Intervention: Alexandrite laser
Number of subjects: 65

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 65
Study: 23022970

Group type: EXPERIMENTAL
Intervention: Colchicine (1.0 mg twice daily for the first day followed by 0.5 mg twice daily for 1 month in patients ≥70 kg; halved doses for patients <70 kg or intolerant)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 360
Study: 19457475

Group type: EXPERIMENTAL
Intervention: Disgust activation (view vomit images)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Neutral activation (view inanimate objects)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Baseline trait disgust propensity
Number of subjects: 46
Study: 17486315

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 14977928

Group type: EXPERIMENTAL
Intervention: Aerosolized Gamma Interferon (IFN-γ)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 21
Study: 11450149

Group type: COMPARATOR
Intervention: CD4+CD45RA+/CD4+CD45RO+ cells ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lymphocytes coexpressing CD45RA and CD45RO antigens
Number of subjects: 0
Study: 10193294

Group type: EXPERIMENTAL
Intervention: Milrinone 50 micrograms kg‐1 administered at the end of bypass
Number of subjects: 0